NeoGenomics, Inc. (NASDAQ:NEO) Receives $13.86 Consensus PT from Analysts

NeoGenomics, Inc. (NASDAQ:NEO) has been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $16.7143.

Several analysts have recently commented on the stock. Craig Hallum reiterated a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research report on Wednesday. Leerink Partners upgraded NeoGenomics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $12.00 to $25.00 in a research report on Wednesday, April 29th. Weiss Ratings raised NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a research note on Wednesday, July 15th. Finally, Needham & Company LLC increased their target price on NeoGenomics from $15.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday.

Key Headlines Impacting NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Quarterly results exceeded expectations. NeoGenomics reported adjusted EPS of $0.05, versus the $0.03 consensus estimate, while revenue reached $201.66 million, ahead of expectations of $196.93 million. Revenue increased 11.2% year over year. NeoGenomics Q2 Earnings, Revenue Rise; Ups Guidance
• Positive Sentiment: Management raised its full-year outlook. NeoGenomics now expects 2026 revenue of $802 million to $806 million, above the approximately $800.3 million analyst consensus. The company also highlighted expected mid-20% growth in next-generation sequencing, supporting the investment case. NeoGenomics 2026 Revenue Outlook
• Positive Sentiment: Needham became more bullish. Needham & Company raised its price target from $15 to $19 and maintained a “Buy” rating, implying additional upside based on the referenced trading level. NeoGenomics Price Target Raised at Needham
• Neutral Sentiment: The earnings call indicated strong demand and growth opportunities, but NeoGenomics adjusted expectations for its pharmaceutical-services business. Investors will watch whether sequencing growth can offset any softness in pharma-related activity. NeoGenomics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the adjusted profit beat, the company continues to report a negative net margin and negative return on equity. The broader analyst consensus remains “Hold,” suggesting some investors may view profitability and execution risks as unresolved. NeoGenomics Consensus Analyst Rating

NeoGenomics Price Performance

NeoGenomics stock opened at $15.27 on Thursday. The firm has a market capitalization of $1.99 billion, a PE ratio of -38.17 and a beta of 1.74. NeoGenomics has a 52 week low of $4.72 and a 52 week high of $16.10. The firm’s 50-day simple moving average is $12.52 and its 200 day simple moving average is $10.67. The company has a quick ratio of 4.06, a current ratio of 4.42 and a debt-to-equity ratio of 0.41.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, July 28th. The medical research company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.02. The firm had revenue of $201.66 million during the quarter, compared to the consensus estimate of $196.93 million. NeoGenomics had a negative net margin of 6.77% and a negative return on equity of 1.96%. The firm’s revenue for the quarter was up 11.2% on a year-over-year basis. During the same period last year, the firm posted $0.03 EPS. On average, equities research analysts predict that NeoGenomics will post -0.15 EPS for the current fiscal year.

Insider Activity

In other news, Director Lynn A. Tetrault sold 5,307 shares of the company’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total value of $59,916.03. Following the sale, the director directly owned 91,422 shares in the company, valued at $1,032,154.38. This represents a 5.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NEO. Royal Bank of Canada boosted its stake in shares of NeoGenomics by 51.2% during the 1st quarter. Royal Bank of Canada now owns 56,026 shares of the medical research company’s stock worth $532,000 after purchasing an additional 18,966 shares during the last quarter. AQR Capital Management LLC purchased a new stake in shares of NeoGenomics during the first quarter worth about $271,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of NeoGenomics by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 75,798 shares of the medical research company’s stock valued at $719,000 after buying an additional 3,254 shares during the period. Intech Investment Management LLC lifted its stake in shares of NeoGenomics by 19.7% during the first quarter. Intech Investment Management LLC now owns 151,806 shares of the medical research company’s stock valued at $1,441,000 after buying an additional 24,965 shares during the period. Finally, Creative Planning boosted its position in NeoGenomics by 20.4% during the second quarter. Creative Planning now owns 16,735 shares of the medical research company’s stock worth $122,000 after acquiring an additional 2,840 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.